Annika Fendler
Overview
Explore the profile of Annika Fendler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
1326
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Furlano K, Keshavarzian T, Biernath N, Fendler A, De Santis M, Weischenfeldt J, et al.
Int J Cancer
. 2025 Jan;
PMID: 39853587
Prostate cancer is a common malignancy that in 5%-30% leads to treatment-resistant and highly aggressive disease. Metastasis-potential and treatment-resistance is thought to rely on increased plasticity of the cancer cells-a...
2.
Fernandez-Sanroman A, Fendler A, Tan B, Cattin A, Spencer C, Thompson R, et al.
Cancer Discov
. 2025 Jan;
OF1-OF23.
PMID: 39784160
Using joint genomic-transcriptomic analysis of 243 samples, we reveal recurrent patterns of nongenetic evolution in ccRCC not exclusively governed by genetic factors, including T-cell depletion, tumor T-cell receptor coevolution, potential...
3.
Fernandez-Sanroman A, Fendler A, Tan B, Cattin A, Spencer C, Thompson R, et al.
Cancer Discov
. 2025 Jan;
PMID: 39774619
While the key aspects of genetic evolution and their clinical implications in clear cell renal-cell carcinoma (ccRCC) are well-documented, how genetic features co-evolve with the phenotype and tumor microenvironment (TME)...
4.
Furlano K, Plage H, Hofbauer S, Weinberger S, Ralla B, Fendler A, et al.
BJUI Compass
. 2024 Nov;
5(11):1081-1089.
PMID: 39539567
Objective: There is a shortage of established prognostic biomarkers in bladder cancer. One candidate is tumour protein 63 (p63), a transcription factor of the p53 gene family that is expressed...
5.
Kluth M, Hitzschke M, Furlano K, Plage H, Hofbauer S, Weinberger S, et al.
Genes Chromosomes Cancer
. 2024 Sep;
63(9):e23271.
PMID: 39324446
17p13 deletions including TP53 and other genes represent a common cause for reduced/lost p53 function in tumor cells. In this study, we analyzed the impact of 17p13 (TP53) deletions and...
6.
Plage H, Dressler F, Fendler A
Eur Urol
. 2024 Aug;
86(5):445-446.
PMID: 39183091
No abstract available.
7.
Plage H, Furlano K, Neymeyer J, Weinberger S, Gerdes B, Hubatsch M, et al.
BJUI Compass
. 2024 Jun;
5(6):585-592.
PMID: 38873357
Objectives: Carcinoembryonic antigen (CEA) is a cell surface glycoprotein that represents a promising therapeutic target. Serum measurement of shedded CEA can be utilized for monitoring of cancer patients. Material And...
8.
Fendler A, Stephan C, Ralla B, Jung K
Int J Mol Sci
. 2024 May;
25(10).
PMID: 38791324
Clinical and preclinical studies have provided conflicting data on the postulated beneficial effects of vitamin D in patients with prostate cancer. In this opinion piece, we discuss reasons for discrepancies...
9.
Plage H, Furlano K, Hofbauer S, Weinberger S, Ralla B, Franz A, et al.
BMC Urol
. 2024 Apr;
24(1):96.
PMID: 38658905
Background: A high level of PD-L1 expression is the most relevant predictive parameter for response to immune checkpoint inhibitor (CPI) therapy in urinary bladder cancer. Existing data on the relationship...
10.
Myszczyszyn A, Popp O, Kunz S, Sporbert A, Jung S, Penning L, et al.
PLoS One
. 2024 Mar;
19(3):e0282938.
PMID: 38512983
Previously, we found that Wnt and Notch signaling govern stem cells of clear cell kidney cancer (ccRCC) in patients. To mimic stem cell responses in the normal kidney in vitro...